Subscribe
aramadourian_flagshippioneering
18 July 2018

LSIPR 50 2018: The entrepreneurial bug

Since its founding in 2000, Flagship Pioneering has set up and fostered the development of more than 100 scientific ventures, resulting in $20 billion in aggregate value, more than 500 issued patents, and more than 50 clinical trials for novel therapeutic agents.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Big Pharma
A guide for life sciences entrepreneurs
22 December 2021   Small companies face the same long product cycles and upfront costs as the big players but have different IP challenges, explains Chad Shear of Fish & Richardson.


Editor's picks

Americas
Trump’s return sparks calls for pro-patent agenda
5 December 2024

Editor's picks

Americas
Trump’s return sparks calls for pro-patent agenda
5 December 2024
Americas
Comparing life sciences IP in Brazil and the US
28 November 2024
Americas
UPC bans Meril Life Sciences from selling infringing heart valve
19 November 2024
Americas
Amgen set for ‘at-risk’ launch of blockbuster eye drug biosimilar
24 October 2024
Americas
Big Pharma counsel embrace AI but data and legal risks loom
24 October 2024
Asia
President Xi sends message to AIPPI’s World Congress
22 October 2024

More on this story

Big Pharma
A guide for life sciences entrepreneurs
22 December 2021   Small companies face the same long product cycles and upfront costs as the big players but have different IP challenges, explains Chad Shear of Fish & Richardson.

More on this story

Big Pharma
A guide for life sciences entrepreneurs
22 December 2021   Small companies face the same long product cycles and upfront costs as the big players but have different IP challenges, explains Chad Shear of Fish & Richardson.

More features

Fed Circ orders Teva to delist five patents from Orange Book
Sarepta wins $115M in patent dispute over muscular dystrophy drug
CREATES Act unfairly tips the scales to generics
LSPN launches its first-ever US awards to celebrate life sciences leaders
Pharma giants seek closure on COVID-19 vaccine rows
How Inhibrx defended a $450m damages suit
‘A marathon and a sprint at the same time’: How we won $452m damages
Judge denies Intellia bid to throw out suit over $100m Regeneron pact